NCT04606446 2026-04-16
KAT6
Pfizer
Phase 2 Recruiting
Clinical Trials
59 trialsNCT04553133 2026-04-13
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07368998 2026-04-13
optINAVO
Hoffmann-La Roche
Phase 2 Recruiting
NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT04796623 2026-04-08
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT07405801 2026-04-06
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT04544189 2026-04-02
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT07498478 2026-03-27
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
TransThera Sciences (Nanjing), Inc.
Phase 2 Recruiting
NCT06428396 2026-03-24
LITESPARK-029
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04576455 2026-03-20
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT06105632 2026-02-13
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Pfizer
Phase 2 Active not recruiting
NCT03781063 2026-01-28
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Sermonix Pharmaceuticals Inc.
Phase 2 Completed
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT05963984 2025-12-26
SUMIT-BC
Carrick Therapeutics Limited
Phase 2 Completed
NCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT05226871 2025-11-25
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
Pfizer
Phase 2 Active not recruiting
NCT04214288 2025-11-20
SERENA-2
AstraZeneca
Phase 2 Active not recruiting
NCT04024436 2025-11-13
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04567420 2025-10-16
DARE
Criterium, Inc.
Phase 2 Recruiting
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT04224272 2025-08-01
A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT06957379 2025-05-04
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Active not recruiting
NCT02675231 2024-11-26
monarcHER
Eli Lilly and Company
Phase 2 Completed
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT02540330 2024-04-03
007
Atossa Therapeutics, Inc.
Phase 2 Terminated
NCT01953926 2024-03-12
SUMMIT
Puma Biotechnology, Inc.
Phase 2 Terminated
NCT05085002 2024-03-12
A Study of Lerociclib in Participants With Advanced Breast Cancer
EQRx International, Inc.
Phase 2 Terminated
NCT03321981 2024-03-07
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
Phase 2 Completed
NCT02894398 2023-03-13
INGE-B
iOMEDICO AG
Phase 2 Completed
NCT02049957 2023-02-08
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Calithera Biosciences, Inc
Phase 2 Completed
NCT02756364 2023-02-08
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
Calithera Biosciences, Inc
Phase 2 Completed
NCT03584009 2022-06-28
Veronica
Hoffmann-La Roche
Phase 2 Terminated
NCT02569801 2021-04-23
HydranGea
Genentech, Inc.
Phase 2 Terminated
NCT03241810 2020-09-02
SHERBOC
Elevation Oncology
Phase 2 Terminated
NCT00313170 2020-01-06
FINDER II
AstraZeneca
Phase 2 Completed
NCT00451555 2019-11-01
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00274469 2019-09-06
FIRST
AstraZeneca
Phase 2 Completed
NCT02970682 2019-07-12
STEM
Evgen Pharma
Phase 2 Completed
NCT02374099 2018-12-14
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
Celgene
Phase 2 Terminated
NCT00728949 2018-06-06
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00752986 2016-12-05
ZACFAST
Sanofi
Phase 2 Terminated
NCT01437566 2016-11-02
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
Genentech, Inc.
Phase 2 Completed
NCT00454805 2016-08-03
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
AstraZeneca
Phase 2 Completed
NCT01528345 2016-07-11
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Novartis
Phase 2 Terminated
NCT00754325 2016-05-26
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Bristol-Myers Squibb
Phase 2 Completed
NCT00372996 2015-10-28
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
Pfizer
Phase 2 Terminated
NCT02115594 2014-10-08
ENCORE305
Syndax Pharmaceuticals
Phase 2 Withdrawn